Investor Relations

Recent Event

22nd Pan-American Congress of Rheumatology 2020 (PANLAR 2020)

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Company Overview

Based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on protein homeostasis via the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe autoimmune diseases. Additionally, KZR-261 is the first clinical candidate for the treatment of cancer from our protein secretion program and is undergoing IND-enabling activities for the program.

Contact Information


Kezar Life Sciences, Inc.
4000 Shoreline Court
Suite 300
South San Francisco, CA 94080
T: (650) 822-5600

Investor Relations

Celia Economides

Transfer Agent

Computershare Trust Company, N.A.
P.O. Box 505000
Louisville, KY 40233
T: 781-575-2879